Navigation Links
Appointment of Dr. Ian Gilham as Chairman of the Board
Date:3/5/2013

LISBON, Portugal, March 5, 2013 /PRNewswire/ --

Biosurfit, a rapidly-growing company focused on the Point of Care medical diagnostic market, is pleased to announce today the appointment of Dr. Ian Gilham as Chairman of the Board.

Previously, Dr. Ian Gilham was Chief Executive Officer of Axis-Shield plc, the in-vitro diagnostics company acquired by Alere in November 2011 for £235M.  Whilst at Axis-Shield, Dr. Gilham held the position of Chief Operating Officer and became Chief Executive Officer in January 2008. Prior to its sale to Alere, Axis-Shield's revenues rose above £100M and the company issued a maiden dividend.  Before joining Axis-Shield, Dr. Gilham was VP Pharmacogenetics at GSK where he was responsible for the delivery of pharmacogentic tests, as well as novel diagnostic tests used in targeting GSK's medicines.  Prior to joining GSK, Dr. Gilham held international general management, marketing, business development and R&D positions with Abbott Laboratories, Celltech and Amersham, gaining wide expertise in the fields of pharmaceuticals and clinical diagnostics.

Commenting on his appointment, Dr. Ian Gilham , said: "I am delighted to join Biosurfit as Chairman of the Board. It is an incredibly exciting time for the company with new opportunities ahead and a chance to support an entrepreneurial team that have developed innovative and potentially game changing technologies into a great new product. Biosurfit has a tremendous potential in Point of Care Diagnostics with its spinit® instrument that is due to be launched in 2013. I look forward to working with the team to help Biosurfit in reaching its great ambitions."

João Garcia da Fonseca , Founder and CEO of Biosurfit, commented: "We are all delighted to have Ian join the team, particularly as w
'/>"/>

SOURCE Biosurfit
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Denver Patients Can Now Easily Find Doctors and Schedule Appointments Online
2. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
3. American Oriental Bioengineering Announces Appointment of Audit Committee Chairman
4. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
5. OceanGate Inc. Expands Board of Directors with Two Key Appointments
6. Aethlon Medical Announces the Appointment of Thomas V. Wornham and Philip A. Ward to its Board of Directors
7. ADVENTRX Announces Appointment Of Chief Medical Officer
8. Aragon Pharmaceuticals Announces Appointment of Faheem Hasnain as Independent Director
9. ADVENTRX Announces Appointment Of Ted W. Love M.D. To Board Of Directors
10. H. D. Smith Names Timothy Booth Corporate VP, Home Healthcare (HHC), In First-of-its-Kind Leadership Appointment
11. Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... February 26, 2015 ABIVAX, a clinical ... vaccines, today announced that it has dosed in ... IIb/III clinical trial of ABX203 which is taking place in ... The study is designed to assess whether ABX203 can deliver ... (CHB) via controlling viral load for a much longer period ...
(Date:2/26/2015)... 2015   HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... million for the fourth quarter ended December 31, 2014, ... for the same period of 2013.  For the fiscal ... a 34% increase compared to revenue of $207.9 million ...
(Date:2/26/2015)... 26, 2015  Caris Life Sciences® today announced ... Genitourinary Cancers Symposium in Orlando, Fla. ... the Audio Poster Tour. Both studies utilized Caris ... service. These studies showed that panomic testing can ... carcinomas (RCC), providing insights that may drive selection ...
Breaking Medicine Technology:ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 2ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 3ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 4ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 5HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 2HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 3HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 4HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 5HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 6HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 7HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 8HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 9HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 10HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 11HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 12Caris Life Sciences' Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma 2Caris Life Sciences' Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma 3Caris Life Sciences' Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma 4Caris Life Sciences' Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma 5
... DATA ), a technology and services company focused ... reported its,operating results for the first quarter of 2008., ... revenue decreased,approximately 41% to $2,088,000 and the Company reported ... both a basic and diluted basis. These,results compared with ...
... data support potential of asenapine in the treatment of ... schizophrenia and bipolar I ... ) today announced that an overview of asenapine clinical trials,from ... of the,American Psychiatric Association in Washington, D.C., May 3-8. Data ...
Cached Medicine Technology:DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7
(Date:2/26/2015)... 2015 Deep Market Research Report on ... study on the current state of the global ... the Chinese situation. , Major companies included in ... Hu-Friedy, Medisporex, Towne Brothers, Teleflex Medical, Landanger, YDM, ... Equipment, Shuanglu, Changshu Henry Medical Instrument, and Kangqiao ...
(Date:2/26/2015)... 2015 “ KnowNote ” was featured on ... latest and coolest mobile applications on the iOS, Android, and ... of NewsWatch, conducted the app review and shared with viewers ... rhythm and in tune. , Learning a musical instrument can ... what if people could take something they already know and ...
(Date:2/26/2015)... Claflin Medical Equipment , a Rhode Island based medical ... based medical equipment distributor, have announced a merger effective ... premier organizations that specialize in equipment and the logistics ... By combining forces, they can now cover the entire ... Claflin will gain even greater reach with their government ...
(Date:2/26/2015)... Pittsburgh, PA (PRWEB) February 26, 2015 ... Chairman J. Robert Baum, Ph.D. is stepping down as ... succeeded by Joseph C. Guyaux, senior vice chairman of ... chief executive officer, PNC Mortgage. Additionally, Highmark Health President ... the chairman of the board of directors of Highmark ...
(Date:2/26/2015)... 26, 2015 Growth in the ... by a EuroMonitor International Report that U.S. men’s ... In response to the robust demand for ... launching a barbering program in partnership with internationally ... Factory” salon. The proprietary curriculum features 10 signature ...
Breaking Medicine News(10 mins):Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 2Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 3Health News:A Modern Way to Learn Music was Featured on NewsWatch Television on January 30, 2015 2Health News:Claflin Medical Equipment Announces Merger with Hospital Associates 2Health News:Highmark Health Appoints Joseph C. Guyaux Chairman of the Board of Directors 2Health News:Highmark Health Appoints Joseph C. Guyaux Chairman of the Board of Directors 3Health News:Highmark Health Appoints Joseph C. Guyaux Chairman of the Board of Directors 4Health News:Bellus Academy Partners with Renowned Hairstylist D.J. Muldoon to Launch Signature Barbering Program 2
... ... tidbits people are learning about their ancestors is not just trivia. This information is highly ... understanding their familial and ancestral past. , ... Doylestown, PA (PRWEB) March 13, 2010 -- Noted author Donna Evans Strauss ...
... (Nasdaq: SIAL ) today announced that it has entered into an agreement with Pfizer under which Sigma-Aldrich will sell approximately 100 Pfizer-developed small ... ... , , ... ...
... 19 year olds and to those currently not in employment in a bid to increase awareness of safety at work. , ... , , ... ... ...
... 15, 2010 The Autism Consortium, an innovative research, ... enhancing clinical care for families with autism spectrum disorders ... study of genetic testing methods for autism spectrum disorders ... early online release in their eFirst pages today and ...
... AllegroMedical.com, ... meaning that just under 13 years, it has served more than a million customers nationwide. ... (Vocus) March 14, 2010 ... website launched in 1997. The first company to sell medical supplies online, it has grown ...
... its kind to date using cardiac computed tomography angiography, ... coronary artery disease are at higher risk of developing ... Henry Ford Hospital researchers say. Researchers analyzed the ... computed tomography angiography and found that those with a ...
Cached Medicine News:Health News:Author Proves What Celebrities are Learning in "Who Do You Think You Are?" is More Important Than They Realize 2Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 2Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 3Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 4Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 5Health News:British Safety Council Offers Free Health and Safety Qualifications 2Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 2Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 3Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 4Health News:Online Medical Supplies Superstore Ships 1 Millionth Order 2Health News:Family history is strong predictor of obstructive coronary artery disease using CCTA 2
Colloidal Gold Sol, 20 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... PalmScan P2000 Pachymeter [i.e., PalmScan P2000] ... operated biometer, which incorporates A-mode pulsed-echo ... to accurately measure the corneal thickness ... eyes. PalmScan P2000 includes two software ...
... PalmScan A2000 A-Scan [i.e., PalmScan A2000] device ... which incorporates A-mode pulsed-echo ultrasound,technology, and thus ... axial length (AL), anterior,chamber depth (ACD), and ... PalmScan A2000,device is also intended for calculating ...
... low TLR (<1%) and stroke rate - ... long-term durability., , , High Radial Strength: ... artery, increasing lumen diameter with chronic outward ... stent shortening, low profile design, Cordis TRUMARK™ ...
Medicine Products: